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INTRODUCTION 
My theses are (a) most of the time we cannot determine which specific 
model applies to one or more sets of data, but only which class of model 
applies ; (b) when linear pharmacokinetics apply, it is usually not necessary 
to determine which model applies ; and (c) when nonlinear pharmacokinetics 
apply, it is necessary to obtain a partial or complete model to make accurate 
predictions. 
VARIETY OF SIMPLE PHARMACOKINETIC MODELS 
AVAILABLE 
As part of the defense of the first thesis, a survey will be made of the simple 
pharmacokinetic models. 
Figure 1 shows the linear mammillary disposition models with from one 
to three compartments. A disposition model is one representing bolus intra- 
venous administration of the drug. In each case, the concentration in com- 
partment 1 is assumed to represent the whole blood (plasma or serum) 
concentration of unchanged drug. There is only one "one-compartment open 
model";  there are three different "two-compartment open models"; there 
are 13 "three-compartment open models." Within each class, the differences 
between the models resides in the compartment or compartments from which 
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Fig. 1. Linear mammillary disposition models having 
from one to three compartments. In each case, the con- 
centration in compartment 1 is assumed to represent the 
measurable concentration of unchanged drug in either 
whole blood, plasma, or serum. 
elimination of drug occurs. In the three-compartment open models, one 
usually assumes rapid transfer to one of the peripheral compartments and 
slow transfer or return of drug to and from the other peripheral compartment. 
In practice, one decides which class of disposition model applies from 
the number of exponential terms which are needed to describe the whole 
blood (plasma or serum) concentration-time curve either following bolus 
intravenous injection or after a constant-rate intravenous infusion. If only 
one expo1~ential term is involved, we assign the one-compartment open 
model. If two exponential terms are involved, we assign the two-compartment 
open model. If three exponential terms are involved, we assign the three- 
compartment open model. However, if we measure only in compartment 1 
we cannot decide which of the three two-compartment open models or which 
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of the 13 three-compartment open models actually applies to a given set of 
data. 
Also, Benet (1) has shown that the number of solvable rate constants, R, 
is given by equation 1, where n is the number of driving-force compartments. 
R = 2n - 1 (1) 
A driving-force compartment is one having one or more exit rate constants. 
Hence, for the two-compartment open models, n = 2 and R = 3. Thus, if we 
assume either model I or II (of the two-compartment open models shown in 
Fig. 1), we can estimate the three rate cons tan ts lusua l ly  designated kt2 , 
k21, and kel. However, if we assume model III (of the two-compartment open 
models shown in Fig. 1), we cannot estimate the four rate constants if 
measurements are made only in compartment 1. 
For  the three-compartment open models, n = 3 and R = 5. Hence, if we 
assume that any one of models I, II, III, VI, VII, and VIII applies, we can 
estimate the five rate constants. However, if we assume that any of the other 
seven three-compartment open models applies, we can only estimate five of 
the total of six or seven rate constants. The real problem, however, is that we 
must assume a particular model;  hence the rate constants estimated are 
peculiar to our arbitrary choice. 
Table I summarizes the linear mammillary disposition models. The 
class, number of driving-force compartments, maximum number of micro- 
scopic rate constants, number of solvable rate parameters, and number of 
possible models are listed. 
A similar set of mammillary disposition models may be formed by 
replacing first-order elimination by Michaelis-Menten elimination kinetics 
(2). Hence one would have to determine a V,, and a Km value instead of a 
first-order elimination rate constant. These nonlinear disposition models are 
summarized in Table II. 
DiSanto and Wagner (3) introduced nonlinear tissue-binding models. 
The general scheme is shown in Fig. 2. It is assumed that there is (are) one or 
Table I. Linear Mammillary Disposition Models 
Number of driving- Maximum number Number of solvable Number of 
Class force compartments ~ of rate constants rate parameters ( 2 n -  1) models 
One 1 1 1 1 
Two 2 4 3 3 
Three 3 7 5 13 
Total 17 
"A driving-force compartment is one with one or more exit rate constants, n = the number of 
driving-force compartments. 
~ 0  Wa~er 
Table II. Nonlinear Mammillary Disposition Models 
Number of driving- Maximum number Number of 
Class force compartments of parameters" possible models 
One I 2 1 
Two 2 6 3 
Three 3 10 13 
Total 17 
~Includes all microscopic first-order rate constants and V,, and K,, values. 
Tissue Type 2,1 Tissue Type 2,2 Tissue Type 2,k 
T A2, C2 - A22 C~ T A2k C2 
] I  t ~ ~ 2  = - -  ~ \ 
" \x~-'~_~" "-2Z 7- " 
l+l , 
\ , '  +, ' P-c,v, ~ \ t /  
\ ' ~  / /  
T T,.-,+, { +  +, 
Tissue Type Tissue Type Tissue Type 
I,I 1,2 l,n 
Fig. 2. General scheme for a nonlinear multicompartment model 
(3) assuming that the drug distributes to one or more homogeneous 
or heterogeneous compartments representing different structural 
regions of the system. The drug is introduced into the fluid or 
aqueous phase of compartment 1 by any input process. This first 
compartment may be homogeneous (single aqueous phase) or 
heterogeneous (aqueous phase perfusing one or more tissues of 
types 1,1, 1 ,2, . . . ,  1,n). The drug in solution in the aqueous phase 
of compartment 1 may also be distributed to the fluid or aqueous 
phase of compartment 2. k12 represents the fraction of drug in the 
aqueous phase of compartment 1 being transferred per unit time 
to the aqueous phase of compartment 2, while k2~ represents the 
reverse transfer. The second compartment may be homogeneous 
(single aqueous phase) or heterogeneous (aqueous phase perfusing 
one or more tissues of types 2,1, 2 ,2 , . . . ,  2,k). In each case, the drug- 
tissue "reaction" may be one or more of ehemical combination, 
binding, complexation, adsorption of drug on surface of tissue cells, 
etc., since the theory does not delineate the mechanism of uptake 
and release of drug by any given tissue. 
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two fluid compar tments ,  designated by the tubelike structures. The relation- 
ship between the tissue concent ra t ion  and the free (non-prote in-bound)  drug 
in the fluid is assumed to obey a Langmuir - type  equat ion in each case. We 
may  have one type of  fluid and only one type of tissue associated with the 
fluid, one fluid and two types of tissue associated with the fluid, etc. We may  
have two fluids and various combina t ions  of  types of  tissues associated with 
the fluids. 
Table I I I  summarizes  the possible models of this class if it is assumed that  
there may  be either one or  two fluids and a m a x imum number  of  three types 
of  tissue associated with each fluid. There are 15 possible models if el imination 
from the inner fluid is assumed to be first order, and another  15 models  if 
el imination is assumed to obey the kinetics of Michaelis and Menten. 
U p  to this time, we have been considering only intravenous administra-  
tion. Suppose now that  we consider oral  or  in t ramuscular  administrat ion.  
If  input to the central compar tmen t  is represented by a single first-order rate 
constant ,  then for each of  the disposit ion models  we obtain one more  model.  
Since there are 17 linear mammil la ry  disposit ion models and 17 nonl inear  
disposit ion models,  we obtain  34 more  models. The 30 tissue-binding models  
give 30 more  models. We may  also have the drug going in both  directions 
across t h e  gastrointestinal barrier  (i.e., input  to the central compar tmen t  
would be ~--72 instead of ~ ) ;  this concept  produces  a further large number  
of addit ional  models. We cannot  distinguish between these two types of  
Table IlL Nonlinear Tissue-Binding Models 
Number of possible models 
Number of fluid Number of tissues Number of tissues 
compartments with fluid No. 1 with fluid No. 2 First order" Michaelis-Menten" 
1 t 0 1 1 
1 2 0 1 1 
1 3 0 1 1 
2 1 0 1 1 
2 2 0 1 l 
2 3 0 1 1 
2 1 1 1 1 
2 1 2 1 1 
2 1 3 1 1 
2 2 1 1 1 
2 2 2 1 1 
2 2 3 1 1 
2 3 1 1 1 
2 3 2 1 1 
2 3 3 1 1 
TotaLs 15 15 
"Refers to type of elimination kinetics from fluid No. I. 
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input by measuring only in blood. If input (or absorption) is represented by 
two compartments, then there are eleven possibilities, and nine of them are 
shown at the bottom of Fig. 3. 
If blood levels following oral administration are fitted by a four-term 
polyexponential equation, and blood levels following intravenous adminis- 
tration are fitted by a two-term polyexponential equation, then there are 
27 possible models to explain the data, as shown in Fig. 3. The disposition 
portion of the model may be any of the three models shown at the top, and 
the input portion of the model may be any one of the nine partial models 
shown at the bottom. It is assumed that the arrowheads on the right-hand 
side of each of the partial input models at the bottom of Fig. 3 connect with 
compartment 1 of the disposition models at the top of Fig. 3. In the example 
cited, it is very difficult, if not impossible, to determine which of the possible 
27 models applies to a particular set of data. 
Another difficulty is the "pooling effect." In the tissue-binding models, 
it is extremely difficult to distinguish plasma protein binding from binding 
of drug to tissue, or binding of drug to one type of tissue from binding to 
THE DISPOSITION PORTION OF THE MODEL COULD BE: 
THE INPUT PORTION OF THE MODEL COU!.D BE: 
HENCE, THE TOTAL NUMBER OF POSSIBLE MODELS = 3 X 9 = 27 
Fig. 3. Possible input and disposition portions of models 
which could describe blood levels following oral adminis- 
tration of a drug where the plasma concentration-time 
curve gives a four-term polyexponential equation and where 
blood levels following intravenous administration give only 
a two-term polyexponential equation. 
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another type of tissue. This is because, in a certain parameter space, a sum 
of two Langmuir equations acts like a single "pooled Langmuir equation." 
Similarly, Sedman and Wagner (4) showed that parallel Michaelis-Menten 
paths could be "pooled." Also, frequently, parallel Michaelis-Menten and 
first-order paths may be "pooled" into one Michaelis-Menten path. 
Table IV summarizes 760 possible models that have been surveyed. In 
addition, there are a large number of flow rate limited models, such as those 
of Bischoff et aL (5); a typical example is shown in Fig. 4. Figure 4 is an 
example of a flow rate limited model elaborated by Bischoffet al. (5) to explain 
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Fig. 4. Blood flow rate limited model posed by Bischoff to explain the 
distribution and excretion of methotrexate in several animal species. 
Symbols:  Q, plasma flow rate to specific organs:  r, drug transport rate in 
bile; ~, nominal  resident time in bile subcompar tments :  C; drug concen- 
trations in gut lumen subcompartments ,  Dashed lines within compar tments  
indicate the possibility of t issue-to-plasma distribution within that com- 
partment.  
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Table IV. Summary of Relatively Simple Pharmacokinetic Models 
Class 
Number of additional models if 
Number of 
possible One-input Reversible Two 
disposition first-order first-order compartments 
models rate constant input for input" 








Nonlinear tissue-binding models d 
First-order elimination 
Michaelis-Menten elimination 
1 1 1 9 
3 3 3 27 
13 13 13 117 
1 1 1 1 
3 3 3 27 
13 13 13 117 
15 15 15 135 
15 15 15 135 
Totals 64 64 64 568 
Grand total = 760 possible models 
"Assumes only first-order rate constants involved in input steps. 
bAssumes first-order elimination. 
CAssumes Michaelis-Menten elimination. 
dAssumes elimination only from fluid compartment No. 1, maximum of two fluid compartments, 
and maximum of three different types of tissue per fluid compartment. 
AIDS IN CHOOSING A CLASS OF MODELS 
Certain types of data aid in choosing a class of model. These are as 
follows : 
a. Whole blood (plasma or serum) concentrations of unchanged drug 
measured as a function of time following bolus intravenous injection 
of several doses of the drug. Samples must be collected very shortly 
after injection and sampling continued long enough to establish the 
log-linear terminal phase with at least four data points or long enough 
to be able to estimate the V,, and K m if elimination kinetics are those 
of Michaelis and Menten. 
b. Whole blood (plasma or serum) concentrations measured as a func- 
tion of time following oral administration of two or more doses of the 
drug given as a solution which dilutes infinitely in the fluids of the 
gastrointestinal tract without precipitation of the drug. 
c. Measurement of the major metabolite of the drug in blood (plasma or 
serum) in the same samples as those in which unchanged drug is 
measured when experiments (a) and (b) are carried out. 
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d. Measurement of the unchanged drug and the major metabolite in 
urine collections obtained at the same time as experiments (a) and (b) 
are carried out. 
WHICH MODEL? 
Often it does not matter which specific model of a class of models is 
chosen. For example, the Loo-Riegelman absorption method (6) assumes 
that model I of the three possible two-compartment open models (see Fig. 1) 
applies. Recently, Wagner (7) has shown that application of the method will 
give the correct asymptote and the correct kinetics of absorption in cases 
where the actual model is any one of the three "three-compartment open 
models." 
The Wagner-Nelson absorption method (8) is based on the one-com- 
partment open model. Recently, Wagner (9) has shown that if the Wagner- 
Nelson method is applied to data obeying the two-compartment open model 
with first-order absorption the Wagner-Nelson data may be resolved to give 
estimates of both ~ and ko. 
The one-compartment open model gives good predictions of average 
steady-state amounts of drug in the body whenever [(fl/kel) (t + k 12/k21 ] ---' 1, 
even though blood levels are best described by the two-compartment open 
model (i0). 
Minimum steady-state blood levels are often well predicted by a simple 
monoexponential equation. This does not mean that the one-compartment 
open model applies, but rather that at z hr after a dose at steady state all 
exponential terms, except one, are essentially equal to zero'. 
WHEN YOU DO NOT NEED A PHARMACOKINETIC MODEL 
My second thesis was that when pharmacokinetics are linear it is usually 
not necessary to determine which specific model applies. I will now defend 
this thesis by showing how to perform many of the needed calculations with- 
out a model in the classical sense. 
Bioava i lab i l i ty  
First-Pass Effect 
The first-pass effect may be assessed using equations 2 and 3 : 
0 = (d~ f~ C~ dt 
(dose)ora I f~ Ci.v. dt 
fm(dose)i.v. 
0 = l - -  




In these equations, C refers to the whole blood (plasma or serum) con- 
centration at time t, the integrals represent the total area under the con- 
centration-time curve, fm represents the fraction metabolized, 2 represents 
the whole blood concentration/plasma concentration ratio, and l?b,1, repre- 
sents the liver blood flow rate. These equations were presented by Rowland 
(11) and were applied to diphenhydramine by Albert et al. (12). In equations 
2 and 3, 0 represents the fraction of the oral dose which reaches the general 
circulation intact. The integrals may be estimated using equations 4 and 5: 
fo ;o C dt = C dt + Cr/fi  (4) 
fo fo C dt = A i e -~it dt = Ai/E i (5) i = 1  i = 1  
The integral on the right-hand side of equation 4 may be estimated by the 
trapezoidal rule directly from the C, t data; here, T represents the last 
sampling time of blood in the study. The area from the last sampling time to 
infinity is estimated by the term on the far right of equation 4; here CT is the 
concentration at time T and fl is the first-order elimination rate constant 
estimated from the very terminal C, t data. To use equation 5, one would fit 
the C, t data to a polyexponential equation using a suitable program and a 
digital computer and then integrate the resulting equation to obtain the 
appropriate area. 
Efficiency o f  Absorption 
The efficiency of absorption of a drug from a solid oral dosage relative 
to a solution of the drug may be assessed using equation 6. 
F = (d~ f'~ CB dt (6) 
(dose)sf~ C A dt 
Here A refers to the reference (or solution) and B refers to the test solid oral 
dosage form. If A represents the intravenous route of administration, then 
the F represents the actual fraction of the oral dose which is absorbed 
(assuming there is no "first-pass" effect). Use of equation 6 involves the 
assumption that the plasma clearance remains constant. Wagner (13) has 
reported on an alternative equation in which the area is multiplied by the fl 
value obtained for the same set of data. 
Rate  o f  Absorption 
Rate of absorption may be assessed without a model for linear systems 
using the deconvolution method introduced by Recigno and Segre (14) and 
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studied extensively by Benet and Chiang (15). The general equations for the 
deconvolution method so as to obtain absorption plots and absorption rate 
constants directly from blood level data are given below for an orally 
administered drug : 
H(t)  = F(O), G(t - 0), dO = F(t)*G(t) (7) 
where H(n) is a function describing the blood concentration-time curve 
following oral administration, F(n) is a function describing the blood con- 
centration-time curve following bolus intravenous administration, and G(n) 
is the transfer function describing absorption. 
From the general equation 8, the equations applicable to calculation of 
individual values of G i are shown below: 
G 1 = H 1 / F  1 
G 2 = (H 2 - 
G 3 = ( H  3 - 
G 4 = (H 4 - 
Gs = (H5 - 
(9) 
F2G1)/F1 (10) 
F2G2 - F3G1)/F1 ( l l )  
F2G3 - F3G2 - F4G1)/F1 (12) 
F2G~ - F3G3 - F4G2 - FsG1)/F1 (13) 
Benet and Chiang (15) recommend use of the point-area (P-A) method 
rather than the point-point  (P-P) or the area-area (A-A) methods. In the 
point-area (P-A) method, H i is equal to the blood (plasma or serum) con- 
centration at time t i after oral administration and F i is equal to the area under 
the bolus intravenous blood (plasma or serum) concentration-time curve 
between ti and t~+ 1- To apply the deconvolution method illustrated here, the 
blood (plasma or serum) concentrations must be measured at equally spaced 
time intervals during the absorption phase, but not at other times. The con- 
centrations have to be measured at the same times following both oral and 
intravenous administration for the time interval that drug is being absorbed 
after oral administration. The accuracy of the method depends on how close 
together the samples are taken during the absorption phase. The same 
situation holds with the Loo-Riegelman method (6,7). Wagner (7) has shown 
that greater accuracy in application of the Loo-Riegelman method may be 
obtained by use of interpolated points as well as the observed data points ; 
the interpolated points were obtained by spiine and Akima methods as 
reported by Fried and Zeitz (16). The same interpolation method may be 
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used  be fo re  a p p l i c a t i o n  o f  the  d e c o n v o l u t i o n  m e t h o d .  Th i s  i n t e r p o l a t i o n  
m e t h o d  is p a r t  o f  the  p r o g r a m  A U T O A N  (17), w h i c h  will  be  desc r ibed  
br ief ly  later.  
T h e  d e c o n v o l u t i o n  m e t h o d  is i l l u s t r a t ed  wi th  s i m u l a t e d  d a t a  in T a b l e  V. 
E q u a t i o n  14 was  used  to  g e n e r a t e  t he  s i m u l a t e d  o ra l  d a t a  s h o w n  in the  f o u r t h  
c o l u m n  o f  T a b l e  V. E q u a t i o n s  15a a n d  15b w e r e  used  to  g e n e r a t e  the  s imu-  
l a t ed  i n t r a v e n o u s  d a t a  a n d  to  ca l cu l a t e  the  a r e a  u n d e r  t he  cu rve  up  to t i m e  ti, 
r espec t ive ly .  
C o ~  120[e  - ~  e -1"~ (14) 
C i 'v" m- 1 0 0 e  - ~  (15a) 
f l  i 100 e -0"17425t/) 573.888(1 e -~  0 (15b) 
C iv" d t  - 0.17425(1 - = - 
Table V. Illustration of the Deconvolution Method a 
t i c i ' v ' d t  F i Hi = C p.~ G i 




















58.63 G1 = 58.63/91.77 = 0.6389 
69.86 G 2 = [69.86-(77.10)(0.6389)]/91.77 = 0.2245 
65.93 Ga = [65.93-(77.10)(0.2245)-(64.76)(0.6389)]/91.77 
= 0.07896 
57.94 G 4 = [57.94-(77.10)(0.07896)-(64.76)(0.2245) 
-(54.41) (0.6389)]/91.77 = 0.0278 
49.57 G 5 = [49.57-(77.10)(0.0278)-(64.76)(0.07896) 
- (54.41)  (0.2245)-(45.71)(0.6389)]/91.77 = 0.00974 
Fraction remaining at Actual fraction 
t l-  1 G i absorption site = GJ0.6389 remaining = e- 1.0455ti- I 
0 0.6389 1.0000 1.0000 
1 0.2245 0.3514 0.3515 
2 0.07896 0.1236 0.1236 
3 0.0278 0.0435 0.0434 
4 0.00974 0.01524 0.01527 
"In G i = -0.4478 - 1.0456 ti_ 1 (r = -1.000)(equation 16),/~o = 1.0456 hr -1 (actual value = 
1.0455 hr- 1). 
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In this simulation, the oral and intravenous doses were assumed to be equal. 
The values listed under "G~" in Table V arose by application of equations 
9-13 to the numbers shown in the third and fourth columns of the table. At 
the bot tom of Table V the time and G~ values are summarized. Equation 16, 
the equation for the least-squares In G~, t i -  1 line 
In Gi = - 0.4478 - 1.0456ti_ a (r = - 1.000) (16) 
is also shown in the table ; the slope of this line is the estimated value of ko 
(absorption rate constant). With these error-free data, the rate constant is 
estimated extremely accurately by the method. One can also calculate values 
of "fraction of drug remaining at absorption site" as shown in the lower 
portion of Table V ; these are compared with the actual values found. 
To apply the deconvolution method in those cases where the one- 
compartment open model applies requires only oral data and not intra- 
venous data. This does not appear to have been stated formerly. An illustra- 
tion is given in Table VI. Once again, equation t4 was used to generate the 
simulated oral data shown in the fourth column of Table VI. Here oral data 
were collected long enough to establish the terminal log-linear line shown 
opposite the data points in the interval 6-12 hr in Table VIo These data were 
used to generate a C*, t equation (equation 17a) in place of the equation for 
intravenous administration of the drug. The C*, t equation is integrated step- 
wise (equation 17b) to obtain areas and the area in each time interval calcu- 
lated as shown under "F~" in the third column in Table VI. 
C* = 118.95 e -~ (17a) 
fo 118.95 e -~ 685.87(I e -~ t, C* dt = 0.17343(1 - = - (17b) 
Equations 9-13 are then applied as before to yield the Gi values shown in the 
fourth column of Table VI. The G~, ti_ 1 values are summarized at the bot tom 
of Table VI; the least-squares In Gz, ti_ 1 equation (equation 18) 
In G i = -0 .6152 - 1.0559t i_ 1 (r = 0.999) (18) 
is shown below the table ; the slope of this line is the estimated value of k~. In 
this case, ko was accurately estimated at an error of only 1% with these 
error-free data using only the simulated oral data. 
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Table VI. Illustration of Deconvolution Method Applied to Oral Data Only (One-Compart- 
ment Open Model)" 
ti C* dt Fi H~ = C p'~ G i 
0 O \  0 
109.21 
/ 








3 278.22 65.93 G 3 = [65.93-(91.82)(0.1883)-(77.19)(0.53686)]/ 
\ 109.21 = 0.06593 
64.91 
/ 
4 343.13 57.94 G4 = [57.94-(91.82)(0.06593)-(77.19)(0.1883) 
\ -(64.91) (0.53686)]/109.21 = 0.02293 
54.57 
/ 







Fraction remaining at Actual fraction 







t l -  1 Gi 
G5 = E49.57-(91.82)(0.02293)-(77.19)(0.06593) 
-(64.91)(0.1883)-(54.57)(0.53686)]/109.21 
= 0.00784 
C* =4.7787 -0.17343t 
or 
C* = 118.95 e -0"17343t (equation 17a) 
remaining = e - 1.0,*55 h_ t 
0 0.53686 1.0000 1.0000 
1 0.1883 0.3507 0.3515 
2 0.06593 0.1228 0.1236 
3 0.02293 0.04271 0.0434 
4 0.00784 0.01460 0.01527 
"ln G~ = -0.6152-1.0559q_ 1 (r = -0.999) (equation 18), fs = 1.0559 hr-1 (1% error) (actual 
value = 1.0455 h r -  1). 
Dosage Regimen Calculations (Linear Systems) 
All  d o s a g e  r e g i m e n  c a l c u l a t i o n s  m a y  b e  p e r f o r m e d  b y  f i t t i ng  e i t h e r  
s i n g l e - d o s e  o r  s t e a d y - s t a t e  b l o o d  ( p l a s m a  o r  s e r u m )  c o n c e n t r a t i o n - t i m e  
d a t a  to  s i m p l e  p o l y e x p o n e n t i a l  e q u a t i o n s ,  a n d  in s o m e  cases  b y  use  o n l y  of  
t h e  t r a p e z o i d a l  r u l e  t o  e s t i m a t e  a reas .  M o d e l  p a r a m e t e r s  d o  n o t  h a v e  to  b e  
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derived from the coefficients and exponents of the polyexponential equations. 
C l ( t  ) = ~ I ie -E't (19) 
i=1 
Equation 19 is a general equation indicating the polyexponential 
equation obtained by fitting blood levels observed following a single dose. 
Here Cl(t ) represents the blood (plasma or serum) concentration at time t 
after the dose, n is the number of exponential terms required to explain the 
data, and I i and El are the coefficients and exponents of the polyexponential 
equation. The corresponding steady-state equation is given as equation 20: 
Css(t) = ~=~{ I~e-~" 
1 - -  e - - = ~  J (20)  
Here, Css(t) refers to the steady-state concentration at time t after a dose at 
steady-state and r is the uniform dosing interval. To obtain the time of the 
maximum concentration at steady state, t~ "X, one differentiates equation 20 
and sets the derivative equal to zero as shown by equation 21 : 
d C s s _ ~ - E i l i e  -e''~'' } 
dt i=~[  ~ Z ~ V  = 0  (21) 
If there are only one or two exponential terms (i.e., n = 1 or 2) in the 
polyexponential equation, then t~ ~ may be obtained from equation 21 by 
the use of logarithms; however, if there are three or more terms (i.e., n > 3), 
then one must solve equation 21 for t~ ~x by an iterative method using an 
electronic calculator or a digital computer. 
Once the value of t~ ax is known, then the maximum concentration at 
steady state may be calculated with equation 22; the minimum concentration 
at steady state is given by equation 23 : 
{ -- E'tmax "~ 
Cs~O~ = Ii e '.,~ (22) 
i=1 1 - e -E~ (23) 
I would like to propose that the ratio of the loading dose/maintenance 
may be calculated using equation 24. This ratio is given by the ratio of the 
area under the curve during a dosage interval at steady state to the area 
under the single-dose curve from time 0 to time z. 
loading dose _ f~o Cs~(t) dt f~ C~(t) dt ZI=I Ii/E~ 
maintenance dose f~o C,(t) dt f~o Cl(t) dt ~'~=1 (Ii/Ei)(1 - e-E~) (24) 
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The use of the above equation gives a slightly higher value for the ratio than 
the method used by Krfiger-Thiemer (18). A comparison of the two methods 
is given below for the one-compartment open model with first-order absorp- 
tion which was always used by Krfiger-Thiemer in dosage regimen calcula- 
tions : 
loading dose C~ in 1 
- - -  - ( 2 5 )  
maintenance dose C• TM (1 - e-K~(1 -- e -k~) 
loading dose Css k - K 
maintenance dose = C=]- = k(1 - e -r~) - K(1 - e -k~) (26) 
Equations 25 and 26 compare the ratio of the loading dose/maintenance 
dose for the one-compartment open model with first-order absorption 
shown. Here k is the absorption rate constant and K is the elimination rate 
constant. The method of Krfiger-Thiemer (18) is indicated by equation 25 ; 
in this method, the required ratio is equal to the ratio of the minimum con- 
centration at steady state to the minimum concentration at z hr after the 
first dose. The method I am proposing gives the ratio equal to the ratio of 
the average concentration at steady state, Css, to the average concentration 
from 0 to z hr after the first dose, C1. This is indicated by equation 26. For 
example, if k = 1.0455, z = 6, and K = 0.17425, then equation 25 gives a 
value of 1.54 and equation 26 gives a value of 1.73. 
If steady-state blood levels are measured at several times after dosing, 
then one could fit the data to equation 20 rather than using single-dose blood 
levels to make predictions. 
If only minimum steady-state blood levels are measured (i.e., blood 
levels just before the next dose), such as in the hospital situation, then a 
model-independent equation is shown as equation 27. This is not useful 
per se but may be written as either equation 28 or 29 depending on what type 
of information is available. 
[- F 7 [-fraction remaining at end of dosage interval-] mln = . . . . . . . . .  DM 
Css L Vo J L fraction lost during dosage interval J 
In most cases, one can write either 




Cs~i" = P[~  ] I  1 -e-P~e -f~ ]Dlvt (29) 
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In these equations, F is the fraction of each dose absorbed at steady state, I/D 
is the volume of distribution, D M is the maintenance dose, ]? is the apparent 
elimination rate constant, and p is a proportionality constant and depends 
on the particular model. Often/3 may be estimated from creatinine clearance 
measurements once a correlation has been established between /~ and 
endogenous creatinine clearance. If equation 28 is used, then one correlates 
the values of C min with values of the product of DM and the part in the square 
bracket involving ~. The proportionality constant or slope of the plot is the 
other part in the square bracket, namely pF/VD. If equation 29 is used, then 
one must have knowledge of the value of F and of V o ; for example, in the 
recent work of Jusko et al. (19) with digoxin. In this case, the proportionality 
constant is p. 
If one is interested only in average steady-state blood levels, then 
equations 30-32 apply to linear systems and some nonlinear systems. 
C s s  - F D ,  (30) 
where 
Css = f',~ Cs~(t) at (31) 
T 
T : 12 2 - -  t I 
Hence 
where 
F _ .f~ 61([7 ) d t  _ I t t  2 Css(t) d~ 
~cl D M  D M  
(32) 
_ (dose)i.v. (33) 
f; c1(0 dt 
The equation of Wagner et al. (20) is written in model-independent fashion 
as equation 30. Here, ~1 is the whole blood (plasma or serum) clearance and 
is defined by equation 33__ The other symbols have been defined before. One 
can obtain the ratio F/l?cl from oral data, as indicated by equation 32. Once 
an average value of this is known or a value for a particular patient, then 
predictions of Css values for various values of z and D M may be made using 
equation 30. Also, the estimate of F/~r may be obtained from blood levels 
measured after a single dose of drug by making a ratio of the area from zero 
to infinite time to the dose. 
Amount of Drug in the Body 
The amount of drug remaining in the body at time t after a bolus intra- 
venous dose may be estimated by measurement of whole blood (plasma or 
serum) concentrations measured at times t, as shown in the following 
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equations. The concentration-time data are fitted to a polyexponential 
equation as indicated by equation 34: 
C =  ~ I ie -e :  (34) 
i = 1  
The clearance is then calculated with equation 35 : 
-~ _ D _ D ( 3 5 )  
gcl f~  C dt 2 7 = 1  I i /E  i 
The amount of drug remaining in the body at time T(AB) is then calculated 
with equation 36. 
A B = D - ~cl C dt = D - ~ (1 - e -e'r) (36) 
i = 1  9 
The volume of the central compartment, V~, may be estimated with equation 
37, and the amount of drug in the central compartment, Ac, at time T calcu- 
lated with equation 38: 
D 
V~ - ~7=* I, (37) 
Ac = V~. C (38) 
The amount of drug in compartments other than the central compartment 
at time T, A0, may be calculated with equation 39 : 
Ao = As - A~ (39) 
Analysis of data by hand or electronic calculator is often laborious and 
requires a prohibitive amount of time. Also, the "answers" obtained by 
digital computer are often better than the "answers" which may be obtained 
either by hand or by electronic calculator. Fortunately, the operations 
involved in pharmacokinetic analysis of data are generally systematic and 
therefore lend themselves to computer programming and solution by 
machine. 
Sedman and Wagner have arranged to distribute the program AUTOAN 
(17) on a world-wide basis. AUTOAN is a Fortran IV digital computer 
program for automatic analysis of concentration-time data described by 
pharmacokinetic models involving first-order and/or Michaelis-Menten 
elimination kinetics. AUTOAN is used in conjunction with the 1969 version 
of the program NONLIN, distributed by Dr. Carl M. Metzler of the Upjohn 
Company in Kalamazoo, Michigan. The combination of AUTOAN and 
NONLIN provides for the complete pharmacokinetic analysis of whole 
Do You Need a Pharmacokinetic Model, and, If So, Which One? 475 
blood (plasma or serum) concentration-time data. Only "raw" concentra- 
tion-time data, and specification of parameters which indicate route of 
administration, weighting scheme desired, etc., are required for its use. 
AUTOAN analyzes concentration-time data as follows: 
a. The presence or absence of Michaelis-Menten kinetics is deter- 
mined. 
b. If elimination kinetics are first order (as determined by the program), 
then the optimum polyexponential equation is fitted to the data; this 
may have from one to five exponential terms. The numerical values 
of the coefficients and the exponents of this optimum equation are 
printed out as well as similar values for lower-degree polyexponential 
equations which were determined in the process of reaching the 
optimum equation. The program then chooses an appropriate model 
for the data set from a library of models and computes initial estimates 
of the parameters of the mode! from the coefficients and exponents 
of the optimum polyexponential equation. 
c. Final least-squares estimated of the model parameters are then 
obtained by NONLIN, performing a nonlinear least-squares fit of 
the data to the chosen model. 
d. If elimination kinetics are those of Michaelis and Menten, the pro- 
gram will analyze the data if they obey the one-compartment open 
model with Michaelis-Menten elimination kinetics ; if a more com- 
plicated disposition model is involved the program will so indicate, 
but does not provide a least squares fit. AUTOAN has been 
thoroughly tested and gives results comparable to or better than 
those obtained by laborious manual techniques. This program 
enables rapid, economical, and ,accurate computer analysis of 
pharmacokinetic data. 
Some advantages of using AUTOAN are as follows : 
a. Data are extended by interpolation of one data point between each 
pair of observed points using spline and Akima methods as reported 
by Fried and Zeitz (16). 3 These interpolated points are used only 
during the derivation of the polyexponential equations and not 
during the final least-squares fitting of the data to the model chosen 
by the computer. 
b. The program does all curve stripping automatically. The optimum 
polyexponential equation reported is, in general, a better one (i.e., 
3A second version of AUTOAN does not interpolate points, and also lag times have been intro- 
duced into the polyexponential equations. Arrangements for modifying the first version to 
include these additions may be made by contacting the author. 
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lower sum of squared deviations) than that which is obtained using 
the back-projection technique and an electronic calculator. 
c. The program uses a statistical criterion to distinguish first-order 
elimination from Michaelis-Menten elimination kinetics. 
d. It automatically chooses one of a library of 17 models and outputs 
results of the nonlinear least-squares fit of the observed data to the 
chosen model. 
e. The results printed out by AUTOAN may be used in model-indepen- 
dent equations, such as reported herein, or the parameters of the 
model chosen by the program may be used in equations for the 
particular model. 
NONLINEAR PHARMACOKINETICS 
My third thesis stated that when nonlinear pharmacokinetics apply it is 
necessary to obtain a partial or complete model to make accurate predictions. 
I will indicate some support for this thesis now. 
DiSanto and Wagner (3) administered five different doses of methylene 
blue to a dog at different times by bolus intravenous injection and measured 
whole blood concentrations as a function of time after each of the doses. 
Each set of concentration-time data was very well fitted to the equations 
appropriate to the two-compartment open model with bolus intravenous 
injection. However, examination of the estimated parameters indicated that 
the parameters changed with dose. Hence one set of parameters was of no 
use in making predictions of whole blood concentrations for another dose 
of the drug. When the same data were fitted to the nonlinear tissue-binding 
model with one type of fluid and one type of tissue, then consistent values of 
the parameters were obtained. Also, it was possible to simultaneously fit 
all five sets of data to the model and estimate only one value of each of A, B, 
and K from the data. Hence, in this case, the nonlinear model appeared to 
adequately describe the data and would allow prediction of blood levels 
following other doses within the same range, and, possibly, outside the range 
studied. 
Historically, it has been assumed that ethyl alcohol is metabolized in 
man at a zero-order or constant rate and that the evidence for this is a 
pseudolinear phase in the blood concentration-time curve for some time 
starting after the peak alcohol concentration and continuing until there is 
marked curvature at the tail end of the curve on Cartesian coordinate graph 
paper. Wagner (21) clearly showed that if Michaelis-Menten elimination 
kinetics apply then the slope of the pseudolinear decline will increase with 
increase in dose; hence the data cannot be explained by zero-order elimin- 
ation. In the paper of Wagner (21), this conclusion was reached by a simula- 
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t ion technique.  However,  we now have h u m a n  data  result ing from adminis-  
t ra t ion  of four different doses of e thanol  to eight different subjects which give 
the same result. We have also data  for seven n o r m a l  volunteers  in whom 
ethanol  was infused at a cons tan t  rate over a 2-hr per iod and  the entire t ime 
course of capil lary b lood  alcohol concen t ra t ions  followed. The downslope 
data  are fitted well to the o n e - c o m p a r t m e n t  open  model  with Michae l i s -  
Men ten  e l iminat ion ,  and  appl ica t ion  of a modif ied W a g n e r - N e l s o n  method  
allowed back-ca lcu la t ion  of the infusion rate with relatively small  errors. 
However,  even after publ ica t ion  of the paper  of Wagne r  (21), the zero-order 
concept is still being repeated (22). There  are still p roblems in in terpre t ing 
some e thanol  b lood  concen t ra t ion  data,  as our  future publ ica t ions  will 
indicate. However,  it does appear  that  the Michae l i s -Men ten  equa t ion  does 
explain the e l imina t ion  phase adequately.  
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